Melane Sampson, Author at BioTuesdays

Developments

FDA accepts Omeros’ BLA resubmission for narsoplimab in TA-TMA

Omeros Corporation (NASDAQ:OMER) announced that the FDA will review its resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated...

May 6, 2025

Developments

WHO approves Moleculin’s name for next-gen anthracycline

Moleculin Biotech (NASDAQ:MBRX) announced that the International Nonproprietary Names (INN) expert committee of the World Health Organization (WHO) has approved “naxtarubicin” as the non-proprietary name of its next...

May 6, 2025

Feature

Terns shaping the future of human health with potential best-in-class therapies for serious diseases

Terns Pharmaceuticals (NASDAQ:TERN) is developing a portfolio of novel, oral small-molecule product candidates based on clinically validated mechanisms of action to address serious diseases including oncology and...

May 6, 2025

Developments

Firefly acquires Evoke Neuroscience—resulting in multi-fold database, IP portfolio, and commercial footprint expansion

Firefly Neuroscience (NASDAQ:AIFF) has announced its acquisition of closely held Evoke Neuroscience, a medical device company developing and commercializing technologies to aid in the comprehensive assessment of brain...

May 5, 2025

Developments

Positive results from Perimeter’s B-Series OCT with ImgAssist AI 2.0 pivotal trial presented at ASBrS 2025

Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) announced that detailed, positive results from the pivotal trial evaluating the use of its next-generation B-Series OCT with ImgAssist AI 2.0 for intraoperative...

May 5, 2025

Developments

electroCore acquires NeuroMetrix gaining access to Quell platform

electroCore (NASDAQ:ECOR) announced it has completed the merger with NeuroMetrix (NASDAQ:NURO), expanding its portfolio to include Quell Fibromyalgia Solution, strengthening its commercial reach, and positioning the...

May 2, 2025

Developments

Profound reports positive perioperative data from randomized CAPTAIN trial comparing TULSA with Robotic Prostatectomy; Lake Street analyst suggests trial data will be well received by payors

Profound Medical (NASDAQ:PROF; TSX:PRN) announced initial perioperative data from its Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA procedure with radical prostatectomy (RP) in men...

April 30, 2025

Developments

Immunic unveils positive data from Phase 2 trial of IMU-838 in progressive MS

Immunic (NASDAQ:IMUX) announced positive Phase 2 CALLIPER data demonstrating its nuclear receptor related 1 (Nurr1) activator—vidofludimus calcium (IMU-838)—reduced the risk of progressive multiple sclerosis (PMS)...

April 30, 2025

Feature

Tasman redefining treatment for hard-to-treat depression with breakthrough oral ketamine monotherapy

Closely held Tasman Therapeutics is shifting the treatment landscape for treatment-resistant depression (TRD) with its registered, proprietary formulation—a first-of-its-kind, oral extended-release ketamine tablet.

April 29, 2025

Executive Moves

Modivcare appoints Daniel Silvers to BOD; three BOD members resign

Modivcare (NASDAQ:MODV) announced that it has appointed Daniel Silvers to its board of directors (BOD), and board members Craig Barbarosh, David Coulter, and Richard Kerley have resigned, effective April 24, 2025. Mr...

April 25, 2025

Author - Melane Sampson

FDA accepts Omeros’ BLA resubmission for narsoplimab in TA-TMA

WHO approves Moleculin’s name for next-gen anthracycline

Terns shaping the future of human health with potential best-in-class therapies for serious diseases

Firefly acquires Evoke Neuroscience—resulting in multi-fold database, IP portfolio, and commercial footprint expansion

Positive results from Perimeter’s B-Series OCT with ImgAssist AI 2.0 pivotal trial presented at ASBrS 2025

electroCore acquires NeuroMetrix gaining access to Quell platform

Profound reports positive perioperative data from randomized CAPTAIN trial comparing TULSA with Robotic Prostatectomy; Lake Street analyst suggests trial data will be well received by payors

Immunic unveils positive data from Phase 2 trial of IMU-838 in progressive MS

Tasman redefining treatment for hard-to-treat depression with breakthrough oral ketamine monotherapy

Modivcare appoints Daniel Silvers to BOD; three BOD members resign

Subscribe